Fc variants with altered binding to FcRn
AssigneeXencor, Inc.
InventorsAaron Keith Chamberlain, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Jost Vielmetter, Sean C. Yoder
Life of this patent
Estimating the term…
Abstract
The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
Claims6
A composition comprising an Fc variant of a wildtype human IgG Fc polypeptide, wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.
A composition comprising a variant Fc domain as compared to a wildtype human IgG Fc domain, wherein said variant Fc domain comprises a serine residue at position 434, and wherein numbering is according to EU numbering.
A polypeptide comprising an Fc variant of a wildtype human IgG1 Fc polypeptide wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.
A composition comprising an Fc variant polypeptide, wherein the Fc variant polypeptide is encoded by a nucleic acid encoding a variant of a wildtype human IgG Fc polypeptide, wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.
A polypeptide encoded by a nucleic acid encoding a polypeptide comprising an Fc variant of a wildtype human IgG Fc polypeptide wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.
A protein comprising an Fc variant of a wildtype human IgG Fc polypeptide, wherein said Fc variant comprises a serine residue at position 434, and wherein numbering is according to EU numbering.
Dependencies are inferred from the claim text.